To attempt to cover concisely 18 years' experience with haloperidol is indeed a gigantic task. Hence, what I shall strive to do is to discuss the art of psychopharmacotherapy with haloperidol and to incorporate some recent techniques of therapy with this neuroleptic.
To me the art of psychopharmacotherapy involves several steps. First, I think it is essential for the psychiatrist to try to make as accurate a psychiatric diagnosis as possible before prescribing any psychoactive drug. Too often doctors administer psychopharmaceuticals solely for symptoms rather than for illnesses. Ideally, neuroleptics should be prescribed for schizophrenia; lithium for bipolar manic depressives, especially for those with hypomania or mania; and tricyclic antidepressants for the illness depression and not the symptom depression. At times therapy solely for symptoms may help, but optimal therapeutic results are more likely to be achieved when psychopharmaceuticals are prescribed in adequate doses for specific illnesses. Secondly, I must stress that we are not really treating schizophrenia or mania or any other psychiatric illness, but a human being who happens to have a particular type of psychiatric illness. Therefore, besides knowing what psychopathology the patient has, it is imperative that we be physicians and know as much as we possibly can about the patient's physical status before we write a prescription for any psychopharmaceutical drug.
Thirdly, there have been enough pharmacogenetic data gathered in the last decade to verify that responsiveness, refractoriness, dosage requirements and side-effects are quite similar among blood relatives. Therefore, I think every psychiatrist should take a family drug history before he decides on a psychopharmaceutical for a patient. Experience has taught me, for example, that a schizophrenic with a family history of non-responsiveness to a particular neuroleptic may be resistant to the same neuroleptic. On the other hand, if there is a family history of responsiveness to a specific psychoactive drug, then the patient is a candidate for treatment with that particular compound.
Fourthly, since we physicians are practising in an era of polypharmacy, it is rare for us to see a patient who is taking only one drug. Hence, it is as important to take a personal drug history as it is to take a family drug history. From the personal drug history we can learn much about the patient as a drug taker; whether he is the type who faithfully adheres to prescription directions, or a 'doit-yourself physician' who takes medicines not as directed but according to his own judgment. Also, from the personal drug history we can learn whether the patient is taking other medicines which should not be co-prescribed with particular psychopharmaceuticals because of possible adverse interactions. Finally, before prescribing a psychoactive drug, a physician should be familiar with at least the elementary pharmacological properties of these medicines. For example, chlorpromazine and haloperidol are neuroleptics, but if one compares the prototype phenothiazine, chlorpromazine, with the prototype butyrophenone, haloperidol, one must acknowledge that they are equi-effective but otherwise different from each other in several important aspects. Fig 1 shows that on a weight for weight basis, haloperidol is more potent than chlorpromazine; that chlorpromazine has a greater propensity than haloperidol to cause sedation, anticholinergic and cardiovascular effects and to alter the convulsive threshold, but that haloperidol has a greater propensity than chlorpromazine to cause extrapyramidal reactions.
In short, although equi-effective, haloperidol is more potent, safer and less likely to cause subjectively distressing side-effects than chlorpromazine. The greater potency of haloperidol is important. The less of any chemical I have to give a patient the happier I am, because I am convinced that there is a relationship between the amount of chemical I give a patient and the amount of toxicity it may cause.
Having made a psychiatric diagnosis, assessed the physical status of the patient, taken the family and personal drug histories and selected a psychopharmaceutical agent, the physician must now decide on the preferable route of administration and estimate what may be the effective dose for the individual patient. A clue to the latter may be provided by the family and personal drug histories and by the nature, severity and duration of the patient's illness. Chronic schizophrenics, for example, are metabolically different from acute schizophrenics and other psychiatric patients and generally, therefore, they require higher doses for optimal therapeutic results. If a blood relative with schizophrenia required 100 mg of haloperidol for a good therapeutic result, it can be assumed with reasonable certitude that the patient may require 100 mg of haloperidol to achieve a comparable therapeutic result. Dosage, however, always has to be individualized, since in a group of patients with the same illness there is a tremendous variation in dosages required to get similar effects. Plasma level studies of various psychoactive drugs have illustrated this repeatedly.
Haloperidol can be administered orally in tablet or liquid concentrate, intramuscularly or intravenously. Although absorption from the intestine is usually very good, when very rapid control of symptoms is desired, intramuscular or intravenous administration is preferable. Consequently, in the United States and elsewhere psychiatrists are treating acutely disturbed patients with a regimen called 'rapid neuroleptization', which is similar in some respects to 'digitalization'. This consists of giving intramuscular doses of haloperidol fairly close together, for example 10 mg injections every 30 minutes. Usually four to six injections (sometimes less) control the more acute patients and halo- peridol is then administered orally as needed. This technique of haloperidol therapy, as well as other forms of intramuscular haloperidol therapy, will be discussed by other speakers in this symposium. Hence, I shall only stress that in my experience intramuscular haloperidol for rapid neuroleptization is safe and efficacious for those patients requiring such therapy.
Why give haloperidol intravenously? There are situations in which it is most desirable to achieve very rapid symptom control in the safest way possible: acute delirium tremens, very severe mania, or a severe malignant catatonic excitement, for example. In such situations, intravenous administration of haloperidol is preferable to waiting for oral or intramuscular doses to be absorbed and effective. Intravenous haloperidol may also be used to control acute agitation in a patient with a recent myocardial infarction or an acute postoperative psychosis. This form of haloperidol therapy can be a very practical, very safe and very efficient way of managing what otherwise would be a difficult management problem for psychiatrists. The intravenous dosage must also be individualized and may range from 2 to 25 mg or more.
For schizophrenia of recent origin and for an acute relapse in a chronic schizophrenic, as well as for the treatment of chronic schizophrenia resistant or only partially responsive to neuroleptic therapy, oral haloperidol may be the treatment of choice. Optimal therapeutic results will be achieved only when psychiatrists administer adequate individualized dosages of haloperidol. For many patients this means dosages in excess of those customarily prescribed. Consequently, many therapists have begun to use high-dose neuroleptic therapy especially for chronic, apparently treatment-resistant schizophrenics, who without such treatment would, or at least might be, prisoners of psychosis indefinitely. In recent years therefore, an escalating number of schizophrenic and other psychotic patients (particularly the former) have been and are being treated with gradual increments of oral or parenteral haloperidol in doses ranging from 30 mg to 200 mg or more daily.
Those experienced with high-dose haloperidol therapy testify that it is remarkably safe and that it does not cause a higher incidence of extrapyramidal reactions than low-dose therapy. In fact, they testify that high-dose haloperidol therapy causes fewer extrapyramidal reactions than low-dose therapy. Nevertheless, high-dose therapy is not without risk. It should be reserved for those chronic schizophrenics most likely to benefit from it. These are physically fit patients under age 40 with acute onset rather than a slow evolution of their psychosis, who have been ill less than 10 years, who have had some response to prior neuroleptic therapy and who are still reacting to their delusions and hallucinations rather than accepting them complacently. Anhedonic schizophrenics are not usually candidates for high-dose haloperidol therapy.
When maximum improvement is reached in these patients, which may not happen for four to six months, haloperidol is reduced gradually to the lowest effective individual maintenance dose; for many patients this may be the 15-20 mg per day. When the patient has been stabilized for several months on a maintenance dose of haloperidol, a regimen of 'drug holidays' should be started.
Haloperidol, like all potent neuroleptics, even in high doses, may cause extrapyramidal reactions ranging from the various manifestations of akinesia to dyskinesia or acute dystonia, akathisia, and parkinsonism. These are a matter of individual sensitivity since they occur solely in neurologically susceptible subjects. Many haloperidoltreated patients never show neurologic effects, even though they have taken equal or larger doses for the same length of time or longer than those in whom striopallidal symptoms develop.
Accumulating pharmacogenetic data indicate that blood relatives tend to have similar sideeffects when treated with the same neuroleptic. There is also evidence that patients who have blood relatives with naturally occurring parkinsonism are more apt to have a neurolepticinduced extrapyramidal reaction. Hence, to anticipate what may happen, physicians should inquire about these predisposing factors before prescribing haloperidol. Patients also should be asked if they have been treated previously with any other neuroleptic and what their response was. Clinical experience with all neuroleptics has revealed that if a patient had a striopallidal reaction to one neuroleptic, he is likely to have a similar reaction to the others. Thus, if a patient has a history of a neurologic response to any other neuroleptic, the chances are he will react similarly to haloperidol.
Although it is widely believed that haloperidol has a greater propensity to cause extrapyramidal reactions than other neuroleptics, this has not been proven by well-designed, rigidly controlled and well-executed comparative studies. Actually, the published studies comparing haloperidol with other antipsychotic drugs, when analysed in toto, indicate that haloperidol is no more liable to evoke striopallidal symptoms than other potent neuroleptics.
Extrapyramidal reactions elicited by haloperidol are neurophysiologic and not toxic effects of this compound. It is possible to control or eliminate them by reduction of dosage, mild sedation, or anti-parkinsonian drugs. They may possibly be avoided by initiating therapy at low doses with gradual increments thereafter. They are not prevented by the prophylactic coadministration of an anti-parkinsonian drug.
These drug-induced neurologic effects are partly dose-related and they are also dependent on the age, sex and physical condition of the patient. Young individuals are most likely to develop dystonic reactions or oculogyric crises. Patients between 16 and 60 years of age are apt to have akathisia. The older the patient, the greater the susceptibility to parkinsonian symptoms. Women seem more inclined to haloperidol-induced striopallidal reactions than men.
The route of administration of haloperidol also seems to play an important role in the incidence of extrapyramidal reactions which this drug may provoke. Paradoxically, the published reports on parenteral administration indicate that intramuscular or intravenous haloperidol, even in relatively high doses, evokes fewer striopallidal symptoms than oral dosage. Why this should be so is inexplicable at present. Some have attributed it to the fact that, orally, haloperidol is absorbed through the hepatic barrier while, intravenously, it goes directly to the target areas. They speculate that haloperidol might undergo transformations in the liver that make it more apt to cause a striopallidal reaction. When it is warranted, clinicians need not refrain from using parenteral haloperidol for fear that it may cause a higher risk of an extrapyramidal reaction than oral administration.
The commonest haloperidol-evoked extrapyramidal reactions are acute dyskinesia or dystonia and akathisia. Dystonic reactions can be relieved promptly by the intravenous or intramuscular injection of 1-2 mg benztropine mesylate or 1-2 mg biperiden, which may be repeated in a half-hour if necessary. Thereafter, oral anti-parkinsonian medication (1-2 mg) should be prescribed every four to six hours for three or four doses. As an alternative therapy, the patient could be given a quick-acting barbiturate, chlorpromazine 25 or 50 mg, or an antihistamine, such as diphenhydramine hydrochloride. Recovery can also be expedited by having the patient lie down in a quiet, darkened room. After recovery, haloperidol may be represcribed in lower doses or concomitantly with an anti-parkinsonian drug, since dystonic re-actions are not a contraindication to further therapy with this drug. Akathisia or motor restlessness is often described by the patient as the 'jitters'. He feels compelled to walk or pace the floor. When standing, the patient may continuously rock his body forward, backward and side to side or constantly shift his weight from one foot to the other. At the same time there may be chewing movements of the jaw, a rolling or smacking of the tongue and a twisting of the fingers.
Akathisia usually appears after the first week of treatment. If the drug is continued, akathisia may be replaced by parkinsonism. Since patients with motor restlessness feel and appear anxious, physicians unfamiliar with this reaction may think haloperidol has not controlled the patient'sanxiety and decrease the dose, or discontinue treatment. Although most patients are annoyed by motor restlessness and will not tolerate it long, neither course of action is necessary. Relief can be achieved by an anti-Parkinson drug orally two or three times daily, often without lowering the dose of haloperidol.
Sometimes only partial relief can be obtained with moderate doses of an anti-Parkinson drug. Larger doses of an anti-Parkinson agent are inadvisable since these compounds exert psychotropic effects of their own and their co-administration in large doses with haloperidol may precipitate a toxic psychosis. Safer control of akathisia can be secured by the simultaneous prescription of moderate doses of an anti-Parkinson drug and a benzodiazepine, like diazepam. If such measures do not relieve severe akathisia the dose of haloperidol should be reduced.
Haloperidol-induced parkinsonism is usually relieved readily by either anti-Parkinson medication or reduction of the dose of haloperidol, or both. Thus, what must be emphasized is that all the early onset striopallidal reactions evoked by haloperidol are reversible either with or without counteracting treatment measures.
I have mentioned the seeming paradox that high doses of haloperidol seldom evoke extrapyramidal reactions. Precisely why is not really known. It could be that since haloperidol has some anticholinergic effects, high doses provide enough anticholinergic action to counteract haloperidol's effects on the dopaminergic system. Another possible explanation is that humans have what I call an upper and a lower neurologic threshold, in between which extrapyramidal symptoms occur. Thus, if the serum level of a neuroleptic is above or below these neurologic thresholds no extrapyramidal symptoms will be elicited. For example, if a 0.25 mg dose of haloperidol is administered, the serum level would be below the lower neurologic threshold and no extrapyramidal reaction would be evoked. A 4 mg dose of haloperidol, however, may produce a serum level between the neurologic thresholds and cause an extrapyramidal reaction, but a 40 mg dose may produce a serum level above the upper neurologic threshold and not cause an extrapyramidal reaction.
It is now well established that any neuroleptic, especially when prescribed in high doses or for months or years continuously, may cause tardive dyskinesia. In contrast to acute dyskinesia (which usually comes on abruptly in the first few days of treatment and is often preceded by or accompanied by subjective anxiety and which usually responds to anti-Parkinson drug therapy) tardive dyskinesia evolves as imperceptibly as the unfolding of a flower, after months of therapy with the responsible neuroleptic. It seldom causes any subjective distress and if not recognized early and managed by dose reduction or discontinuation of the neuroleptic, is resistant to all chemotherapeutic remedies for striopallidal reactions. In fact, anti-Parkinson drugs may make the symptoms worse.
Thus far, tardive dyskinesia has not been reported in patients treated only with haloperidol. Nevertheless, haloperidol could cause this neurological disorder, especially if patients being treated with this neuroleptic are not monitored carefully and regularly. Although tardive dyskinesia has been considered irreversible, new data from my studies indicate that this is not always true. These data suggest that if tardive dyskinesia is detected early and the dose of the responsible neuroleptic is reduced or discontinued, then the symptoms will remit within a few months. On the other hand, if the responsible neuroleptic is not stopped until after the patient has bucco-linguomasticatory symptoms and choreiform or athetoid movement of the extremities, the symptoms may not remit for several years.
Since the risk of tardive dyskinesia can be minimized by early detection, it is imperative that we be physicians and say to patients, 'Open your mouth and stick out your tongue'. If the patient has an emerging tardive dyskinesia you will notice vermiculiform movements ofthe tongue or that the tongue cannot be protruded for more than a few seconds. Such warning signs of tardive dyskinesia should prompt at least immediate reduction of the dose of the neuroleptic. If the dosage is reduced or discontinued at this early stage of tardive dyskinesia, there will be a complete resolution of symptoms.
The longer tardive dyskinesia exists before the neuroleptic is reduced or discontinued, the longer it takes for tardive dyskinesia to remit, but it will remit to at least some degree. The new data I have gathered from years of studying patients with tardive dyskinesia show that many patients with this neurologic complication, after three years of being off all neuroleptics, have remarkable reduction in symptomatology. Those that do not have a substantial amelioration of symptoms within three years are the ones who had a fully developed tardive dyskinesia before neuroleptic therapy was discontinued.
Recent experience with haloperidol also has verified that many patients can be treated with single daily doses of this neuroleptic. This new technique of haloperidol therapy is, like the 'drug holiday' regimen, particularly suited for chronic patients who have been stabilized on maintenance therapy. For such patients the total daily requirement can be administered safely in a single dose, preferably at bedtime, without loss of therapeutic benefit. Compliance with a once-aday haloperidol dosage regimen is high because it is convenient for patients, especially outpatients who can take their needed medication in privacy before retiring. Furthermore, this method of therapy is more economical than therapy with divided daily doses. Not only can patients take the less expensive, higher unit doses of the medication, but a bedtime dose is often sufficiently sedative to obviate the need for a hypnotic.
Conclusion
Almost eighteen years' clinical experience with haloperidol has verified repeatedly the efficacy and safety of this neuroleptic when prescribed in adequate individualized dosage for appropriately selected patients. Clinical experience in the last five years has also shown that if a therapist uses different routes of administration of haloperidol, he can manage safely and effectively a variety of acute and chronic psychiatric illnesses. For many patients this requires flexibility not only in the use of the various ways in which haloperidol can be administered but also frequently in prescribing doses in excess of those customarily prescribed in the past. Not all patients benefit from haloperidol but it is now evident that many acutely disturbed patients can have their symptoms rapidly controlled by intramuscular or intravenous haloperidol therapy and that adequate individualized doses of this drug may benefit optimally some patients refractory to all previous neuroleptic therapy. DISCUSSION Dr P E Garfinkel (Toronto) commented on Dr Ayd's suggestion that tardive dyskinesia was more likely to be shown by patients on multiple neuroleptics. He asked if there was any evidence, when a neuroleptic was taken with a tricyclic antidepressant, that either the plasma level of the neuroleptic was increased or that tardive dyskinesia was more likely to develop in the long term.
Dr Ayd said that this important question had recently been debated by the Food and Drug Administration. There was evidence that desipramine did inhibit the metabolism of butaperazine with a consequent rise in the plasma level of the latter. This work had been repeated several times.
It raised the question whether commercial products and combination products like perphenazine and amitriptyline increased the risk of tardive dyskinesia. They might, if there was any correlation between plasma levels and the incidence of tardive dyskinesia, a relation which had yet to be established. However, he had been unable to obtain any clinical evidence that this was so. This might have been because the patients studied had not been on the combination sufficiently long; they might not have been of the right age or the right sex to show the effect. None the less, the theoretical risk remained. Studies which had compared high-dose with lowdose chlorpromazine or high-dose trifluoperazine with low-dose administration clearly showed that patients on high doses were more at risk of developing tardive dyskinesia than those treated with lower doses. Dr B Alapin (St Albans) suggested that an uncommon but known side-effect of haloperidol was depression. He asked whether there was any parallel between the frequency of depression as a side-effect of haloperidol and the dosage in which it was administered.
Dr Ayd said he did not believe that haloperidol caused depression per se. It could cause a pseudodepression, which was an extrapyramidal phenomenon seen more often in patients on low doses of the drug. To observe it with high doses was exceptional.
The differential diagnosis between true melancholia or extrapyramidal reactions caused by haloperidol could be made by giving an antiparkinsonian drug. Giving such a drug intravenously, extrapyramidal symptoms that were only 'so-called' depressive symptoms cleared within 30 minutes. But if the haloperidol dose was maintained, symptoms returned.
There were patients who could become depressed when being treated with any neuroleptic agent. Dr Ayd cautioned against the use of neuroleptics alone for the treatment of melancholia, because there was evidence that tardive dyskinesia occurred more often in manic depressives than in schizophrenics. Such evidence came to light in the United States where there was a strong anti-psychiatry movement, one of whose aims had been to make it very difficult for patients to obtain ECT. Frequently, patients who would have received ECT in the past were now being treated with neuroleptics, particularly if they were agitated or had some paranoid symptomatology, together with their affective disorder. A proportionately large number of these people were beginning to develop tardive dyskinesia, which would indicate that the manic depressive was more sensitive than the schizophrenic might be.
Dr P Storey (London) disagreed with Dr Ayd and thought that haloperidol was a depressing drug. When used in hypomania, as the patient's mood came down with haloperidol he thought it sensible to lessen the dose to try to smooth out a possible depressive 'bottoming' effect.
Dr Storey also believed that following advertisements which indicated to general practitioners that haloperidol was a useful tranquillizer, administration of small doses produced quite distinct depression in more patients than those who had been given diazepines, although at such low doses (1-1.5 mg twice or thrice daily) there were no parkinsonian side-effects.
Dr Ayd agreed that there was very little extrapyramidal reaction until a dose level of about 4 mg per day. The highest incidence was seen in patients on 4-20 mg daily. Patients on lower doses might not develop overt parkinsonian symptoms, but at the same time they might have extrapyramidal symptoms manifested by changes of mood rather than by neurological effects. If the dose were reduced the mood change would disappear or the administration of anti-parkinsonian drugs would frequently relieve this socalled mood change.
Dr Ayd agreed about reducing the dose of haloperidol when treating hypomanic or manic patients as symptoms ameliorate. It was important because otherwise the patient might well go 'below the line' into a depression. But there was another reason. These drugs bound themselves to body tissues and serum levels dropped very slowly. To keep the patient on the same dose was a therapeutic error, particularly with a bipolar manic depressive.
Dr A J Coppen (Epsom) asked Dr Ayd to comment on the concomitant use of lithium and haloperidol, one of the commonest combinations in the United Kingdom, especially in the treatment of the acute manic patient.
Dr Ayd said that this was a much debated issue after a recent paper reporting irreversible toxicity allegedly due to the combination (Cohen W J & Cohen N H, 1974, Journal of the American Medical Association 230, 1283). Closer inspection of this report, however, revealed that the patients had been mistreated and that they had had lithium in too high a dose for too long. In effect, the description was one of lithium intoxication.
It was well known that the antimanic effects of lithium might require five to seven days to become apparent. Dr Ayd's standard procedure was therefore to start with haloperidol and lithium together in relatively low doses and, after the patient's symptoms began to subside (perhaps five or six days), to reduce the dose of haloperidol immediately and stop it completely within 7-10 days, then relying exclusively on lithium, particularly in the manic depressive bipolar patient who had had repeated episodes in the past. He had never had any difficulty with this procedure. However, he believed that large doses of haloperidol and large doses of lithium together would produce some side-effects, particularly extrapyramidal, which would not occur with the same dose of either drug alone. He did not know whether other kinds of toxicity could occur; nor whether lithium in any way altered the metabolism of haloperidol.
Dr A 0 Forsman (Gothenburg) said that he had seen no change in serum concentration or protein binding of haloperidol induced by lithium.
Dr Ayd confirmed that he had not seen any effect of haloperidol on lithium levels. He was now glad to hear of Dr Forsman's studies showing that lithium had no effect on the metabolism of haloperidol. Serum levels were the same as those that would be expected without lithium. He thought this corresponded to clinical experience. He considered a combination of haloperidol and lithium to be the treatment of choice for mania and even for certain hypomanic patients. It was preferable to trying lithium alone. Most American doctors tended to use haloperidol and lithium. Some used chlorpromazine but patients (especially manics) objected to the obtunding effect that chlorpromazine or any sedative neuroleptic had on them. They were more difficult to manage because they would not comply with their treatment.
Dr S J Dencker (Gothenburg) returned to the question of lowering parkinsonian symptoms with high dosages. Dr Ayd had suggested that this could be due to an anticholinergic effect but the patient usually showed no other anticholinergic signs and he felt there might be some other reason.
Dr Ayd agreed that there were no peripheral signs of anticholinergic effects but this did not mean that a central effect was not occurring. Observations both with a recent antimuscarinic test and with guinea-pig ileum as well as brain preparations, suggested that the higher the haloperidol dose the more anticholinergic effects were observed.
Professor W Linford Rees (Chairman) asked Dr Dencker if he accepted this view of increased anticholinergic effects within the central nervous system witlh increasing dosage.
Dr S J Dencker (Gothenburg) said that the question had been discussed for years but the problems remained.
Dr L J Clein (Epsom) discussed a case which related to possible depressing effects of haloperidol. One extremely ill, severely agitated patient who had been a manic-depressive and had then suffered from agitated depression and continual restlessness for two years in hospital had not responded to any antidepressant or antidepressant combination of drugs. Since three courses of ECT had failed it was decided to refer her for leucotomy about seven years previously. Because of her husband's objection to the operation, in a despairing effort she had been put on haloperidol 3 mg three times daily and her depression and agitation completely cleared up. That this was not a spontaneous recovery was shown by the fact that when the haloperidol was reduced, she relapsed. However, she never went back into hypomania and was able to return to work as a physiotherapist in a hospital in East London. Some years ago a colleague of Dr Clein working with potent neuroleptics had advocated discontinuous treatment which first provoked severe parkinsonian effects. The treatment was then to be stopped and re-started. Despite reservations, Dr Clein initiated such a trial with very high doses of trifluoperazine. Surprisingly he found that patients given 30-40 mg three times daily needed no anti-parkinsonian drug. At the time he had no explanation but the finding had obviously been borne out by more recent studies.
Dr A 0 Forsman (Gothenburg) returned to the question of anticholinergic effects. He said that such drugs as nitrazepam, clozapine and haloperidol in high dosages increased salivation. It was obvious that peripheral anticholinergic effects were not occurring but the central effects could still occur with clozapine as well as haloperidol. Further evidence supporting this suggestion about the former drug was currently being produced in his laboratory in Gothenburg.
Dr J C Maerz (Fort Washington) said the question of depressive features was one of the commonest to be addressed to McNeil Laboratories. A retrospective attempt was being made to study all depressive features as well as to carry out a double blind study against tricyclic antidepressants.
This work was still in progress, but the immediate answer was that about 50% of patients with depressive features seemed to be helped by haloperidol. Depression was unmasked in 20% and aggravated in a further 20%. These figures were comparable to those for tricyclic antidepressants, where 50-600% of patients were helped; in 20% depressive features seemed to be unmasked and in a further 20 % they were aggravated. This study should be available in February 1976.
A further point to be borne in mind was that low doses produced not extrapyramidal effects so much as confounding of emotions, which might be why neurotics in particular were uneasy on haloperidol. Dr Maerz believed that in the Soviet Union this effect was being exploited for more sinister purposes.
Dr A Amidsen (Risskov) found it difficult to interpret recent reports in the literature on lithium toxicity because lithium was eliminated so quickly. The timing of the last dose must be known to assess the status of the patient. These reports indicated irreversible toxic effects from lithium intoxication rather than from haloperidol.
Dr D H Morgan (Birmingham) said that on two occasions he had used haloperidol in people with encephalitis. He had done it with trepidation within a general hospital setting.
Dr Ayd had never used the drug on patients with encephalitis, though he would be wary about giving any potent neuroleptic in this situation, where the blood brain barrier might be altered.
Dr D H Morgan (Birmingham) said that he had had no trouble with the two patients involved. They were very difficult to contain within a general ward setting.
Dr Ayd urged Dr Morgan to publish this finding, since it was important that other doctors, who might be equally wary, should know what had been done. Dr G Silverman (Southall) asked, in those cases where tardive dyskinesia had followed haloperidol, what was the average dosage, duration of administration and the mean age at which the complaint was diagnosed.
Dr Ayd said the condition was more common after the age of 50 than before, although the youngest patient he had seen with unquestionable tardive dyskinesia was 27. The majority of patients were having not a single neuroleptic but multiple therapy, and so it was difficult to know which drug was causing the problem. Most cases of tardive dyskinesia had been discove'red in patients who had been on medication for 2-8 years. A careful watch on patients, however, should show its emergence in as short a period as 3 months.
On discontinuing the drug, patients with mild symptomatology were almost all free within one year, although the condition recurred when putting them back on medication. However, patients with severe buccolingual masticatory syndrome could take from 18 months to 3 years to clear up after all neuroleptics were discontinued.
Finally, patients with severe symptomatology with choreiform athetoid movements, together with hemibalismus had now been followed for 6 years. There was a gradual reduction in the intensity of their symptoms but not a complete amelioration. It might be completely irreversible in some patients, although so far no one was sure. The physician's duty was carefully to monitor the patient and at the first signs to reduce or even discontinue the neuroleptic therapy. There was little value in clearing up the psychosis, if the patient could not live in the community. Dr B M Saran (Coulsdon) asked what evidence there was that large doses of haloperidol would not produce longer term side-effects which were not extrapyramidal but which were effects on some other body system. One such possibility might be side-effects in the eyes.
Dr Ayd said that he had followed patients on haloperidol continuously for 10 years or more. They had been carefully monitored with slit lamp and other observations and so far no signs had been seen of ophthalmological toxicity. Indeed, apart from tardive dyskinesia, haloperidol seemed to be a relatively nontoxic drug given over a long period of time.
Dr Ayd did not believe that everyone should receive the drug. But he did believe that candidates for neuroleptic therapy should be given a single rather than multiple treatment. He knew of no evidence that multiple neuroleptics were more efficacious than a single therapy given in adequate dosage, or that multiple neuroleptics in low doses produced fewer side-effects than an adequate dosage of a single neuroleptic agent.
There were, however, some occasions when administration of two drugs was preferable to one. Lithium and haloperidol were an example for acute mania. Sometimes sedation was required. In that case chlorpromazine could be used with a neuroleptic for its sedative effects. He believed that this should be a short-term use, reverting back to a single neuroleptic once the need for the combination had ceased, since combinations were generally used to treat symptoms rather then to produce a specific antipsychotic effect. He knew of no instance where antipsychotic efficacy was increased by giving two neuroleptics.
Dr P Kristjansen (Roskilde) said that tardive dyskinesia sometimes developed weeks or months after discontinuation of neuroleptic therapy. The way to stop it at that time was to readopt neuroleptic treatment with small doses of haloperidol, pimozide or some other blocker of dopamine receptors. He had seen incipient oral dyskinesia in patients receiving combinations of neuroleptics with anti-parkinsonian drugs. Sometimes discontinuation of the latter solved the problem and then the neuroleptic continued at a reduced dosage. Anti-parkinsonian agents had no beneficial effect whatever in tardive dyskinesia. If anything they would aggravate it.
Dr Ayd agreed. He found that about 80% of patients who had drug induced neurological reactions like parkinsonism lost these symptoms when the anti-parkinsonian agent was withdrawn after 3 months, even though the dose of neuroleptic was unaltered. In only about 20% did the symptoms reappear in a sufficiently troublesome form for anti-parkinsonian medication to be reintroduced.
Dr Ayd advocated 'drug holidays' which were feasible, economical and which worked. Such drugs saturated the tissues and it was a rare patient who, once stabilized, could not be without medication for at least 24 hours. The initial problem was to reassure patients, who were obsessive people and who might believe that medicine must be taken three or four times daily, that to go without it for a short period would not produce a resurgence of symptoms. Although the evidence was limited, it seemed that patients on a drug holiday regimen over a three-year period had a lower incidence of tardive dyskinesia than those on continuous neuroleptic therapy.
Not only should doctors strive for drug holidays, but once the high dose therapy had elevated the patient from a personal psychosis, his status and dosage requirements were changing. The physician should then strive for the lowest possible maintenance dose. Over this period there should be a progressive reduction in the amount of medication given.
In conclusion, Dr Ayd thought that tardive dyskinesia could be minimized by the appropriate use of drug dosages; by monitoring the patient and by withdrawing the medication at the earliest signs of the problem, if it was at all possible to do so.
Chairman's Summing Up by Professor W Linford Rees (St Batholomew's Hospital, London ECI) A drug has been defined as any substance which when injected into a cat produces a paper. Haloperidol has been injected into animals, as we have heard, and has produced 2200 papers. This morning we have had a wide range of information about the action of haloperidol, ranging from animal studies to pharmacodynamics and pharmacokinetics, and the clinical contribution which Dr Ayd has presented to us. We have heard that haloperidol in contrast to chlorpromazine has specific antagonistic effects to apomorphine; it specifically blocks dopamine receptors and increases the turnover of dopamine. It is also antagonistic to the action of amphetamines. These are specific effects when compared with chlorpromazine. However, its action in producing ptosis and its action on tryptamine are different from chlorpromazine. These two measures relate to sedative action and haloperidol, as we have heard from many speakers, has much less sedative action than chlorpromazine. Similarly, its action on the a-adrenergic receptors is much less than chlorpromazine and this fits with clinical observations that it has very little action or side-effects involving the cardiovascular system. Compared with chlorpromazine it is more potent weight for weight, it has a longer duration of action and it has a more rapid onset of action.
The next paper dealt with individual variations in the effect of haloperidol, particularly relating to its pharmacodynamic and pharmacokinetic actions and Dr Forsman described the three elements which were involved in this variation: the disease itself; the tissue responsiveness; and the concentration of the drug at the site of action. He showed how there was quite marked variation between individuals when on the same dose of drug. This was a variation of about tenfold. But we heard from others that this was much less than one finds with other neuroleptics and with tricyclic antidepressants.
Dr Forsman described how the sedative effects, whatever they are, come on within one hour, but there was a long delay of 12 to 16 hours before the extrapyramidal side-effects appeared. He described in detail the metabolic pathways and, in discussion, he referred to the fact that there was no evidence of any enzyme induction with haloperidol, and that the oral doses compared with parenteral administration had a longer half-life. He felt that this might be explained in terms of enterohepatic recirculation. He also pointed out the need for further research correlating serum levels with therapeutic effects. Dr Ayd very comprehensively described the clinical uses of haloperidol and described the appearance, disappearance and re-emergence of extrapyramidal side-effects according to the dosage. He discussed in detail dystonic reactions and parkinsonian side-effects and effective ways in which these can be managed. He also dealt in detail with the very troublesome tardive dyskinesia, a problem which worries us all, both in terms of effective ways of controlling it and also of trying to avoid its appearance in the first place. I think the discussion has been excellent throughout the morning, and I would like to thank all the speakers for keeping to the time allotted with immaculate conscientiousness and also to thank the discussants for their contributions.
